INmune Bio, Inc. (INMB)
1.225
+0.02
(+1.24%)
USD |
NASDAQ |
Jun 11, 12:19
INmune Bio EPS Diluted (Quarterly) : -0.2034 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.2034 |
| December 31, 2025 | -0.198 |
| September 30, 2025 | -0.2434 |
| June 30, 2025 | -1.050 |
| March 31, 2025 | -0.4329 |
| December 31, 2024 | -0.4137 |
| September 30, 2024 | -0.5991 |
| June 30, 2024 | -0.5048 |
| March 31, 2024 | -0.6116 |
| December 31, 2023 | -0.4684 |
| September 30, 2023 | -0.4755 |
| June 30, 2023 | -0.3622 |
| March 31, 2023 | -0.3642 |
| December 31, 2022 | -0.3255 |
| September 30, 2022 | -0.4305 |
| June 30, 2022 | -0.381 |
| March 31, 2022 | -0.3863 |
| December 31, 2021 | -0.542 |
| September 30, 2021 | -0.5458 |
| June 30, 2021 | -0.4444 |
| Date | Value |
|---|---|
| March 31, 2021 | -0.3181 |
| December 31, 2020 | -0.2377 |
| September 30, 2020 | -0.3649 |
| June 30, 2020 | -0.1952 |
| March 31, 2020 | -0.1926 |
| December 31, 2019 | -0.2152 |
| September 30, 2019 | -0.285 |
| June 30, 2019 | -0.0386 |
| March 31, 2019 | -0.2025 |
| December 31, 2018 | -0.193 |
| September 30, 2018 | -0.1372 |
| June 30, 2018 | -0.5503 |
| March 31, 2018 | -0.2537 |
| December 31, 2017 | -0.0382 |
| September 30, 2017 | -0.0274 |
| June 30, 2017 | -0.0147 |
| March 31, 2017 | 0.0027 |
| December 31, 2016 | -0.012 |
| September 30, 2016 | -0.0048 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Sangamo Therapeutics, Inc. | -0.0796 |
| Arrowhead Pharmaceuticals, Inc. | -0.932 |
| Oncolytics Biotech, Inc. | -0.0823 |
| Sarepta Therapeutics, Inc. | 2.878 |
| Anixa Biosciences, Inc. | -0.0772 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.407M |
| Total Expenses (Quarterly) | 5.407M |
| Enterprise Value | 12.32M |
| Earnings Yield | -138.3% |
| Normalized Earnings Yield | -99.12 |